CORPHEDRA Drug Patent Profile
✉ Email this page to a colleague
When do Corphedra patents expire, and when can generic versions of Corphedra launch?
Corphedra is a drug marketed by Endo Operations and is included in one NDA.
The generic ingredient in CORPHEDRA is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Corphedra
A generic version of CORPHEDRA was approved as ephedrine sulfate by SANDOZ on August 23rd, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CORPHEDRA?
- What are the global sales for CORPHEDRA?
- What is Average Wholesale Price for CORPHEDRA?
Summary for CORPHEDRA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 21 |
| Patent Applications: | 551 |
| What excipients (inactive ingredients) are in CORPHEDRA? | CORPHEDRA excipients list |
| DailyMed Link: | CORPHEDRA at DailyMed |
Pharmacology for CORPHEDRA
| Drug Class | Norepinephrine Releasing Agent alpha-Adrenergic Agonist beta-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
| Physiological Effect | Increased Norepinephrine Activity |
US Patents and Regulatory Information for CORPHEDRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Operations | CORPHEDRA | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208943-001 | Jan 27, 2017 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
